Elcella and Calocurb, natural supplements developed in the UK and NZ, respectively, aim to mimic synthetic diabetes medications' weight-loss effects by stimulating 'fullness hormones' GLP-1 and PYY, with promising but limited human trial results.
Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.
The Fall-Winter 2023 fashion shows saw a significant drop in plus-size models, contrasting with previous seasons' limited progress. This rollback coincides with the widespread availability and discussion of new injectable weight loss medications, prompting concerns about the industry's commitment to body diversity and its potential impact on beauty standards.
Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.
Despite new GLP-1 drugs and Medicare coverage, most employers aren't covering them for weight loss due to high costs. Many are exploring alternative support methods for employees.
Despite new GLP-1 drugs and Medicare coverage, most employers aren't covering them for weight loss due to high costs. Many are exploring alternative support methods for employees.
A growing number of Indian couples are using GLP-1 injections like Ozempic and Mounjaro for rapid weight loss before their weddings, driven by societal pressure and social media expectations. Medical professionals express concern over misuse, potential counterfeits, and health risks.
A growing number of individuals are using GLP-1 injections like Ozempic and Mounjaro for rapid weight loss to meet conventional beauty standards for weddings, rather than for genuine health concerns. This trend alarms medical professionals due to potential health risks, counterfeit drugs, and unsustainable results.
The once-daily Wegovy weight loss pill, containing semaglutide, is now available privately in the UK, though not yet on the NHS. It works similarly to the injectable version by mimicking a gut hormone to reduce appetite and increase fullness, requiring a BMI of 30+ or 27-30 with weight-related conditions. Strict guidelines apply for taking the pill on an empty stomach, and costs range from £99 to £199 per month.
Companies are increasingly using "turnkey" telehealth services to quickly launch virtual clinics, even without prior medical experience. These services handle operations, from staffing to compliance, allowing businesses in various sectors to enter the lucrative health market, raising questions about quality and regulation.
A Cyclospora parasite outbreak has infected 145 people across 17 U.S. states between May 1 and June 16. Symptoms include watery diarrhea, nausea, and fatigue. Twenty individuals have been hospitalized, with New York reporting the highest concentration of cases. Officials suspect food contamination as the source, as no travel outside the U.S. was reported by infected individuals.
El Dr. López-Nava aboga por un enfoque integral para la obesidad, combinando fármacos como Ozempic con cambios en el estilo de vida. Advierte que los medicamentos son una ayuda temporal y sin modificación de hábitos, el peso se recupera.
Ben Duckett scored his first Test century in over a year, attributing his success to a post-winter fitness regime and significant weight loss. He aims to maintain this form for as long as possible.
White House officials have denied reports that President Donald Trump received early access to an experimental weight loss drug, retatrutide. A STAT report indicated a 79-year-old patient was granted access via "compassionate use," sparking speculation due to the patient's age matching Trump's at the time.
Many insurance plans are dropping coverage for GLP-1 drugs like Zepbound and Wegovy for weight loss, leaving patients like Deborah Finley struggling to afford them. Experts suggest navigating coverage by checking fine print, filing appeals with doctor support, documenting care, seeking discounts, and being cautious with compounded versions.
The Food and Drug Administration (FDA) is considering stricter border controls for GLP-1 weight loss drugs due to illegal imports from China and online platforms. The agency is also proposing amendments to the Pharmaceutical Affairs Act to hold online platforms accountable for hosting illegal drug sales.
Poolbeg Pharma will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS), a dangerous side-effect of cancer immunotherapy. The drug could improve patient safety and save healthcare systems millions by allowing treatment outside specialist centers.
A nutritionist advises that excessive protein intake, especially when combined with insufficient vegetables and carbohydrates, can hinder metabolism, lead to fat accumulation, and cause fatigue, constipation, and thirst. She recommends balanced meals with plant-based proteins and complex carbohydrates for sustainable weight loss and muscle gain.
The article explores drug repurposing, highlighting GLP-1 agonists like Ozempic and Wegovy, initially for diabetes, now used for weight loss, cardiovascular health, and more. It also discusses COVID-19 treatments like dexamethasone and baricitinib, and historical examples like raloxifene, thalidomide, BCG vaccine, and Viagra, emphasizing both the benefits and potential risks of using drugs for unapproved conditions.
The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
US regulators are warning consumers about potential kidney problems linked to GSK's Alli weight loss pill. The FDA identified 12 cases of kidney complications and advises those with kidney history to consult a doctor.
This report covers three health topics: distinguishing chest pain from heart issues vs. muscle strain, the benefits of adding honey to tea, and a study on gut bacteria aiding long-term weight maintenance.
Recent studies suggest GLP-1 obesity treatments may reduce cancer risk, showing correlation with decreased incidence in 6 out of 7 cancers, potentially through anti-inflammatory effects beyond weight loss.
Dr. Emily Leeming clarifies that sugar itself isn't inherently harmful but rather the context in which it's consumed, highlighting the importance of overall diet quality and distinguishing between added 'free sugars' and natural sugars in whole foods.
